PriceTargets.com logo

Insulet - PODD Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $243.21
  • Forecasted Upside: 46.00%
  • Number of Analysts: 15
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 12 Buy Ratings
  • 0 Strong Buy Ratings
$166.58 As of 04/23/2024 04:34 PM ET
▲ +2.16 (1.31%)

This chart shows the closing price for PODD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Insulet Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PODD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PODD

Analyst Price Target is $243.21
▲ +46.00% Upside Potential
This price target is based on 15 analysts offering 12 month price targets for Insulet in the last 3 months. The average price target is $243.21, with a high forecast of $330.00 and a low forecast of $184.00. The average price target represents a 46.00% upside from the last price of $166.58.

This chart shows the closing price for PODD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 15 contributing investment analysts is to moderate buy stock in Insulet. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 12 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2022
  • 0 strong buy ratings
  • 12 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
1/29/2023
  • 0 strong buy ratings
  • 12 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
4/29/2023
  • 0 strong buy ratings
  • 12 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
7/28/2023
  • 0 strong buy ratings
  • 12 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
10/26/2023
  • 0 strong buy ratings
  • 12 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
1/24/2024
  • 0 strong buy ratings
  • 12 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/24/2024
  • 0 strong buy ratings
  • 12 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
4/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 12 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/26/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$214.00 ➝ $213.00Low
2/23/2024Piper SandlerLower TargetOverweight ➝ Overweight$250.00 ➝ $230.00Low
2/23/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$190.00 ➝ $225.00Low
2/5/2024Stifel NicolausBoost TargetHold ➝ Hold$163.00 ➝ $208.00Low
12/21/2023Robert W. BairdUpgradeNeutral ➝ Outperform$180.00 ➝ $238.00Low
12/4/2023Morgan StanleyUpgradeEqual Weight ➝ Overweight$185.00 ➝ $234.00Low
11/3/2023Piper SandlerLower TargetOverweight ➝ Overweight$325.00 ➝ $250.00Low
10/17/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$325.00 ➝ $162.00Low
10/16/2023Leerink PartnrsReiterated RatingOutperformLow
10/16/2023SVB LeerinkInitiated CoverageOutperform$184.00Low
10/2/2023Jefferies Financial GroupUpgradeHold ➝ Buy$260.00 ➝ $240.00Low
9/29/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$208.00 ➝ $185.00Low
9/15/2023Raymond JamesLower TargetOutperform ➝ Outperform$299.00 ➝ $228.00Low
9/6/2023UBS GroupLower TargetNeutral ➝ Neutral$270.00 ➝ $215.00Low
8/24/2023Bank of AmericaLower TargetBuy ➝ Buy$365.00 ➝ $295.00Low
8/24/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$343.00 ➝ $208.00Low
8/21/2023Robert W. BairdDowngradeOutperform ➝ Neutral$320.00 ➝ $219.00Low
8/21/2023CitigroupUpgradeNeutral ➝ Buy$273.00 ➝ $265.00Low
8/10/2023BarclaysLower TargetEqual Weight ➝ Equal Weight$329.00 ➝ $257.00Low
8/9/2023Raymond JamesLower TargetOutperform ➝ Outperform$350.00 ➝ $299.00Low
8/9/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$365.00 ➝ $325.00N/A
8/9/2023TD CowenLower TargetOutperform ➝ Outperform$350.00 ➝ $300.00N/A
8/9/2023Piper SandlerLower Target$360.00 ➝ $325.00Low
8/9/2023Robert W. BairdLower Target$370.00 ➝ $320.00Low
8/9/2023CitigroupLower TargetNeutral ➝ Neutral$319.00 ➝ $273.00Low
8/9/2023Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$375.00 ➝ $330.00Low
7/10/2023CitigroupLower Target$330.00 ➝ $319.00Low
5/8/2023BarclaysBoost Target$292.00 ➝ $329.00Low
5/5/2023UBS GroupBoost Target$328.00 ➝ $360.00Low
5/5/2023Piper SandlerBoost Target$340.00 ➝ $360.00Low
5/5/2023Robert W. BairdBoost Target$350.00 ➝ $370.00Low
4/20/2023Stifel NicolausBoost TargetHold$300.00 ➝ $342.00Low
4/17/2023BTIG ResearchBoost TargetBuy$340.00 ➝ $350.00Low
3/28/2023UBS GroupInitiated CoverageNeutralLow
2/24/2023Morgan StanleyBoost TargetEqual Weight$320.00 ➝ $325.00Low
2/24/2023Raymond JamesBoost TargetOutperform$320.00 ➝ $334.00Low
2/24/2023Robert W. BairdBoost TargetOutperform$340.00 ➝ $350.00Low
2/24/2023BarclaysBoost Target$245.00 ➝ $292.00Low
1/26/2023Wolfe ResearchInitiated CoveragePeer PerformN/A
1/6/2023Morgan StanleyBoost TargetEqual Weight$300.00 ➝ $320.00Low
1/4/2023BarclaysBoost Target$238.00 ➝ $245.00Low
12/12/2022Robert W. BairdBoost Target$315.00 ➝ $340.00Low
12/12/2022CitigroupBoost Target$270.00 ➝ $330.00Low
11/4/2022Canaccord Genuity GroupBoost TargetBuy ➝ Buy$290.00 ➝ $310.00Low
11/4/2022BTIG ResearchBoost Target$285.00 ➝ $320.00Low
11/4/2022CitigroupBoost Target$260.00 ➝ $270.00Low
11/4/2022Morgan StanleyBoost TargetEqual Weight$273.00 ➝ $300.00Low
11/4/2022Piper SandlerUpgradeNeutral ➝ Overweight$235.00 ➝ $340.00Low
11/4/2022Robert W. BairdBoost TargetOutperform$300.00 ➝ $315.00Low
11/4/2022Raymond JamesBoost TargetOutperform$280.00 ➝ $320.00Low
10/17/2022BarclaysInitiated CoverageEqual Weight$238.00Low
10/12/2022Jefferies Financial GroupInitiated CoverageHold$260.00Low
8/9/2022CitigroupBoost Target$260.00N/A
8/9/2022BTIG ResearchBoost Target$285.00N/A
8/8/2022Morgan StanleyBoost TargetEqual Weight$244.00 ➝ $273.00Low
8/8/2022Canaccord Genuity GroupBoost TargetBuy ➝ Buy$250.00 ➝ $290.00Low
8/5/2022Canaccord Genuity GroupBoost TargetBuy$250.00 ➝ $290.00Low
8/5/2022Robert W. BairdBoost TargetOutperform$245.00 ➝ $300.00Low
8/5/2022Raymond JamesBoost Target$262.00 ➝ $280.00Low
8/5/2022Piper SandlerBoost TargetNeutral$230.00 ➝ $235.00Low
7/11/2022CitigroupDowngradeBuy ➝ Neutral$310.00 ➝ $250.00N/A
6/24/2022BTIG ResearchLower TargetBuy$310.00 ➝ $250.00Low
6/7/2022Morgan StanleyLower TargetEqual Weight$268.00 ➝ $244.00Low
5/17/2022CitigroupLower TargetBuy$350.00 ➝ $310.00N/A
5/6/2022Wells Fargo & CompanyLower Target$357.00 ➝ $345.00High
3/2/2022Bank of AmericaInitiated CoverageBuy ➝ BuyHigh
2/25/2022Morgan StanleyLower TargetEqual Weight$300.00 ➝ $268.00High
2/24/2022Raymond JamesLower TargetOutperform$329.00 ➝ $280.00High
2/24/2022Robert W. BairdLower Target$315.00 ➝ $275.00High
2/24/2022Piper SandlerLower TargetNeutral$295.00 ➝ $230.00High
2/3/2022BTIG ResearchUpgradeNeutral ➝ Buy$320.00Medium
2/2/2022UBS GroupUpgradeNeutral ➝ Buy$325.00Low
1/31/2022OppenheimerUpgradeMarket Perform ➝ Outperform$300.00 ➝ $275.00High
1/7/2022Morgan StanleyLower TargetEqual Weight$303.00 ➝ $300.00High
12/7/2021SVB LeerinkReiterated RatingBuyHigh
11/8/2021Raymond JamesBoost TargetOutperform$285.00 ➝ $329.00Medium
11/5/2021Morgan StanleyBoost TargetEqual Weight$276.00 ➝ $303.00High
11/5/2021SVB LeerinkBoost TargetOutperform$300.00 ➝ $350.00High
11/5/2021CitigroupBoost TargetBuy$325.00 ➝ $350.00High
11/5/2021Piper SandlerBoost TargetNeutral$262.00 ➝ $295.00High
8/6/2021SVB LeerinkLower TargetOutperform$325.00 ➝ $300.00High
8/6/2021CitigroupBoost TargetBuy$310.00 ➝ $325.00High
7/21/2021CowenBoost TargetOutperform$285.00 ➝ $310.00Low
7/20/2021SVB LeerinkBoost TargetOutperform$300.00 ➝ $325.00Low
5/24/2021BarclaysInitiated CoverageOverweight$300.00Low
5/7/2021Raymond JamesLower TargetOutperform$296.00 ➝ $285.00High
5/7/2021SVB LeerinkLower TargetOutperform$320.00 ➝ $300.00High
5/7/2021Piper SandlerLower TargetNeutral$260.00 ➝ $250.00High
5/7/2021BTIG ResearchReiterated RatingHoldHigh
4/1/2021SVB LeerinkUpgradeMarket Perform ➝ Outperform$275.00 ➝ $320.00Low
3/2/2021SVB LeerinkBoost TargetMarket Perform$255.00 ➝ $275.00Low
2/25/2021OppenheimerBoost TargetMarket Perform$235.00 ➝ $277.00High
2/24/2021SVB LeerinkReiterated RatingMarket Perform$255.00 ➝ $275.00High
2/24/2021Raymond JamesBoost TargetOutperform$282.00 ➝ $296.00Low
2/1/2021BTIG ResearchReiterated RatingHoldLow
1/29/2021Piper SandlerDowngradeOverweight ➝ Neutral$260.00Medium
1/15/2021Wells Fargo & CompanyReiterated RatingBuyMedium
12/16/2020Smith Barney CitigroupDowngradeBuy ➝ Neutral$255.00 ➝ $268.00Medium
12/15/2020Morgan StanleyBoost TargetEqual Weight$246.00 ➝ $276.00Low
11/5/2020UBS GroupBoost TargetNeutral$230.00 ➝ $245.00Medium
11/5/2020Wells Fargo & CompanyBoost TargetOverweight$250.00 ➝ $266.00High
11/5/2020Raymond JamesBoost TargetOutperform$249.00 ➝ $250.00High
11/5/2020Morgan StanleyBoost TargetEqual Weight$232.00 ➝ $246.00High
10/12/2020SVB LeerinkBoost TargetMarket Perform$240.00 ➝ $255.00Low
8/7/2020Morgan StanleyBoost TargetEqual Weight$222.00 ➝ $232.00High
8/7/2020OppenheimerReiterated RatingHold$235.00Medium
8/7/2020StephensBoost TargetPositive ➝ Equal Weight$165.00 ➝ $230.00Medium
8/7/2020SVB LeerinkBoost TargetMarket Perform$215.00 ➝ $240.00Medium
8/7/2020Raymond JamesBoost TargetOutperform$200.00 ➝ $249.00Medium
8/7/2020CitigroupBoost TargetBuy$200.00 ➝ $255.00Medium
8/6/2020Piper SandlerReiterated RatingOverweight$235.00 ➝ $260.00Medium
7/28/2020Wells Fargo & CompanyInitiated CoverageOverweight$231.00High
7/7/2020CowenBoost TargetPositive ➝ Outperform$220.00 ➝ $230.00Low
6/9/2020Raymond JamesLower TargetOutperform$220.00 ➝ $200.00Low
5/8/2020CfraBoost TargetSell$162.00 ➝ $179.00Low
5/8/2020UBS GroupBoost TargetNeutral$195.00 ➝ $213.00High
5/8/2020Stifel NicolausBoost TargetHold$161.00 ➝ $195.00High
5/8/2020JPMorgan Chase & Co.Boost TargetOverweight$200.00 ➝ $235.00High
5/8/2020Robert W. BairdBoost Target$189.00 ➝ $242.00High
5/8/2020Morgan StanleyBoost TargetEqual Weight$186.00 ➝ $222.00Medium
5/8/2020SVB LeerinkBoost TargetMarket Perform$200.00 ➝ $230.00High
5/8/2020CitigroupBoost TargetBuy$206.00 ➝ $250.00High
4/27/2020Raymond JamesBoost TargetOutperform$205.00 ➝ $220.00Medium
4/24/2020SVB LeerinkDowngradeOutperform ➝ Market PerformLow
4/3/2020Bank of AmericaInitiated CoverageNeutral$200.00Medium
3/31/2020Berenberg BankDowngradeBuy ➝ HoldHigh
3/27/2020Morgan StanleyBoost TargetEqual Weight$181.00 ➝ $186.00Low
3/27/2020CitigroupLower TargetBuy$220.00 ➝ $206.00Medium
3/4/2020CitigroupInitiated CoverageBuy$220.00Low
2/26/2020Piper SandlerReiterated RatingBuy$200.00High
2/26/2020CowenReiterated RatingBuyHigh
2/26/2020CfraLower TargetSell$163.00 ➝ $162.00Low
2/26/2020Robert W. BairdLower TargetOutperform$225.00 ➝ $215.00High
2/26/2020BTIG ResearchReiterated RatingHoldHigh
2/26/2020Raymond JamesLower TargetOutperform$213.00 ➝ $205.00High
2/6/2020Raymond JamesBoost TargetOutperform$158.00 ➝ $213.00Medium
12/20/2019JPMorgan Chase & Co.Boost TargetOverweight$170.00 ➝ $200.00Medium
12/17/2019Morgan StanleyBoost TargetEqual Weight$148.00 ➝ $181.00Low
12/10/2019CfraInitiated CoverageSell$163.00Medium
11/18/2019Piper Sandler CompaniesBoost TargetOverweight$170.00 ➝ $200.00Low
11/6/2019Raymond JamesBoost TargetOutperform$135.00 ➝ $158.00High
11/6/2019Piper Sandler CompaniesReiterated RatingOverweight$160.00 ➝ $170.00High
10/22/2019Stifel NicolausInitiated CoverageHold$163.00High
10/21/2019CowenSet TargetBuy$165.00Medium
10/14/2019BTIG ResearchDowngradeBuy ➝ NeutralMedium
10/4/2019UBS GroupDowngradeBuy ➝ Neutral$155.00 ➝ $160.00Low
10/3/2019GuggenheimDowngradeBuy ➝ NeutralMedium
9/24/2019SVB LeerinkBoost TargetOutperform$160.00 ➝ $185.00High
9/23/2019Piper Sandler CompaniesReiterated RatingBuyLow
8/6/2019Morgan StanleyBoost TargetEqual Weight$127.00 ➝ $135.00High
8/6/2019BTIG ResearchBoost TargetBuy$140.00High
8/6/2019BMO Capital MarketsBoost TargetOutperform$130.00 ➝ $150.00High
8/6/2019Jefferies Financial GroupBoost TargetBuy$105.00 ➝ $140.00High
8/6/2019Raymond JamesBoost TargetOutperform$125.00 ➝ $135.00High
8/6/2019GuggenheimBoost TargetBuy ➝ Positive$100.00 ➝ $145.00High
8/6/2019JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$120.00 ➝ $155.00High
8/6/2019Piper Sandler CompaniesBoost TargetOverweight$130.00 ➝ $160.00High
7/16/2019Morgan StanleyBoost TargetEqual Weight$98.00 ➝ $127.00Low
7/10/2019SVB LeerinkReiterated RatingOutperformLow
6/28/2019Piper Sandler CompaniesBoost TargetOverweight ➝ Positive$110.00 ➝ $130.00High
6/27/2019JPMorgan Chase & Co.Boost TargetNeutral$90.00 ➝ $120.00Low
6/13/2019UBS GroupBoost TargetBuy$110.00 ➝ $130.00Low
6/10/2019Northland SecuritiesDowngradeOutperform ➝ Market Perform$100.00Low
5/6/2019BTIG ResearchUpgradeNeutral ➝ Buy$115.00High
(Data available from 4/23/2019 forward)

News Sentiment Rating

1.11 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 16 very positive mentions
  • 16 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
9/26/2023
  • 25 very positive mentions
  • 26 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
Mentions as of
10/26/2023
  • 19 very positive mentions
  • 20 positive mentions
  • 7 negative mentions
  • 0 very negative mentions
Mentions as of
11/25/2023
  • 10 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
12/25/2023
  • 15 very positive mentions
  • 24 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/24/2024
  • 30 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/23/2024
  • 27 very positive mentions
  • 21 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
3/24/2024
  • 16 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/23/2024

Current Sentiment

  • 16 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Insulet logo
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Read More

Today's Range

Now: $166.58
Low: $164.61
High: $168.82

50 Day Range

MA: $173.42
Low: $163.25
High: $197.14

52 Week Range

Now: $166.58
Low: $125.82
High: $335.91

Volume

326,488 shs

Average Volume

864,729 shs

Market Capitalization

$11.66 billion

P/E Ratio

57.24

Dividend Yield

N/A

Beta

0.98

Frequently Asked Questions

What sell-side analysts currently cover shares of Insulet?

The following Wall Street sell-side analysts have issued reports on Insulet in the last year: Bank of America Co., Barclays PLC, Citigroup Inc., Jefferies Financial Group Inc., JPMorgan Chase & Co., Leerink Partnrs, Morgan Stanley, Piper Sandler, Raymond James, Robert W. Baird, Stifel Nicolaus, StockNews.com, SVB Leerink LLC, TD Cowen, UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for PODD.

What is the current price target for Insulet?

14 Wall Street analysts have set twelve-month price targets for Insulet in the last year. Their average twelve-month price target is $243.21, suggesting a possible upside of 46.0%. Wells Fargo & Company has the highest price target set, predicting PODD will reach $330.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $184.00 for Insulet in the next year.
View the latest price targets for PODD.

What is the current consensus analyst rating for Insulet?

Insulet currently has 3 hold ratings and 12 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for PODD.

What other companies compete with Insulet?

Other companies that are similar to Insulet include Teleflex, Globus Medical, Abiomed, Baxter International and NovoCure. Learn More about companies similar to Insulet.

How do I contact Insulet's investor relations team?

Insulet's physical mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier's listed phone number is (978) 600-7000 and its investor relations email address is [email protected]. The official website for Insulet is www.insulet.com. Learn More about contacing Insulet investor relations.